Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Scher on Using the Circulating Tumor Cells Test

June 30th 2011

Dr. Howard Scher from MSKCC on Using the Circulating Tumor Cells Test

Dr. Vogelzang Discusses Cabozantinib's Dose Size

June 29th 2011

Dr. NJ Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib's Dose Size

Dr. Scher on the Future of the Circulating Tumor Cell Test

June 28th 2011

Dr. Howard Scher from Memorial Sloan-Kettering on the Future of the Circulating Tumor Cell Test

Donna Berry on Prostate Cancer Patients' Challenges

June 28th 2011

Donna Berry on the Challenges Patients With Prostate Cancer Face

Dr. Scher on Circulating Tumor Cells in Prostate Cancer

June 27th 2011

Dr. Howard Scher from Memorial Sloan-Kettering on Circulating Tumor Cells in Prostate Cancer

FDA Roundup, Including Latest on Avastin Hearing

June 24th 2011

The FDA recently approved a new drug formulation, mandated label changes for cigarettes and sunscreens, and issued an opinion on breast implants.

Dr. Scher Discusses Circulating Tumor Cells

June 23rd 2011

Dr. Howard Scher form Memorial Sloan-Kettering Cancer Center Discusses Circulating Tumor Cells

Dr. Vogelzang Describes Cabozantinib's Side Effects

June 21st 2011

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Dr. Vogelzang on Cabozantinib Clinical Trial Results

June 20th 2011

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

Digoxin Found to Be Effective in the Fight Against Prostate Cancer

June 17th 2011

A search for potential chemopreventive agents for prostate cancer uncovered an unlikely candidate in digoxin, one of the oldest drugs for cardiovascular disorders

Novel Hormone-Radiation Therapy Approaches

June 11th 2011

Radiation therapy (RT) used in combination with hormonal approaches continues to be a viable strategy for treating localized, high-risk prostate cancer patients

Immunotherapies: Avoiding Collisions Once the Brake Is Released

June 11th 2011

Immunotherapies made headlines in oncology last month when the Centers for Medicare & Medicaid Services (CMS) decided that the anticancer vaccine sipuleucel-T (Provenge) will be a payable expense for prostate cancer.

PSA: To Screen or Not to Screen?

June 10th 2011

Screening for prostate cancer does work, despite controversy about its efficacy

Bone-Targeted Therapeutics

June 10th 2011

Therapies that target bone metastases have been developed for more than a decade.

Integrating New Hormonal Therapies in Advanced Disease

June 10th 2011

Hormonal therapies have long been the standard of care for metastatic advanced prostate cancer

The Overtreatment of Prostate Cancer

June 10th 2011

Increased prostate cancer screening has led to overtreatment and has not significantly reduced mortality rates in prostate cancer.

Novel vaccine approaches: Prospects for PROSTVAC-VF Are Bright

June 8th 2011

PROSTVAC-VF uses the smallpox viral vector to stimulate the immune system.

Circulating Tumor Cells Show Promise as Surrogate for Survival in Prostate Cancer Trials

June 5th 2011

Prostate cancer research lacks surrogate biomarkers for survival that could hasten the study and approval of new medications.

ADT for Prostate Cancer May Lead to Rapid, Significant Weight Gain

June 1st 2011

New data show that most prostate cancer patients who receive androgen-deprivation therapy gain a significant amount of weight within a year of starting treatment

High-Risk Care Varies Widely

May 31st 2011

Many clinicians are not employing radiation therapy used in combination with androgen deprivation therapy even though guidelines suggest they should